stem cell retraction, page-17

I would like to clarify some information between Tissue Therapies and shareholders. Can tissue therapies please verify each one of these points?

1. Did Tissue Therapies claim to have made the worlds first serum free and feeder cell free embryonic stem cell media using the VitroGro formulation?
2. Did Tissue Therapies licence this formulation to Invitrogen?
3. Did Invitrogen fail to release a product based on this formulation?
4. Did you have two external companies (Australian Stem cell Centre and Stem Cell Sciences) test the VitroGro media formulation and did they find that it did not support embryonic stem cells?
5. Did tissue therapies scientists submit a paper to stem cells and development that contained errors in almost every figure in the Manton et al. paper (2010)?
6. Was this paper retracted by the Journal?
7. In the paper review process of the Manton et al. (2010) paper, did tissue therapies scientists tell stem cells and development editors that no one else had tested the media with other cell lines when in fact other labs had?
8. Was this untrue at the time?
9. Are you planning to republish the Manton et al. (2010) data set?
10. Did you claim to have cultured two cells lines when in fact you knew at best you had only cultured one?
11.Did your 2009 NHMRC grant application (553028) contain modified data in its only two figures, which you changed during your editing?

I’m really looking forward to the answers, as I’m sure all shareholders are.